




ATTORNEY'S DOCKET NO.: H00535.70012.US
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
TECH CENTER 1600/2900
NOV 19 2002
1600
2900

Applicant(s): Howard Green, et al.
Serial No.: 09/620,783
Conf. No.: 4731
Filed: July 21, 2000
For: LINKAGE OF AGENTS USING MICROPARTICLES
Examiner: D. Naff
Art Unit: 1651

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to BOX RCE, Commissioner for Patents, Washington, D.C. 20231, on November 7, 2002.


Maria A. Trevisan, Reg. No. 48,207

BOX RCE
Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL

Sir:


Transmitted herewith are the following documents:

- Request for Continued Examination (RCE) Transmittal
- Amendment in response to Office Action dated May 7, 2002
(including Appendix A – Marked-up Claims)
- Lemaitre abstract (previously cited in February 11, 2002 IDS)
- Check in amount of \$830.00 (RCE and three month extension of time – small entity)
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617)720-3500, Boston, Massachusetts.

If any further fee is determined to be due, the Examiner is authorized to charge said small entity fee to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,


Maria A. Trevisan, Reg. No. 48,207
WOLF, GREENFIELD & SACKS, P.C.
600 Atlantic Avenue
Boston, MA 02210-2211
Attorneys for Applicant(s)
Tel. no. (617) 720-3500

Attorney's Docket No.: H00535.70012.US
Date: November 7, 2002
X11.07.02

RECEIVED
NOV 19 2002
CH CENTER 16001800

**REQUEST FOR CONTINUED
EXAMINATION (RCE)
TRANSMITTAL**

~~Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995. See The American Inventors Protection Act of 1999 (AIPA).~~

Application Number	09/620,783 NOV 1 1998 SEARCH CENTER 16001
Confirmation Number	4731
Filing Date	July 21, 2000
First Named Inventor	Howard Green
Group Art Unit	1651
Examiner Name	D. Naff

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

application.
NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, you may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) instead of an RCE to be eligible for the patent term adjustment provisions of the AIPA.

1. Submission required under 37 C.F.R. § 1.114
 - a. Previously submitted
 - i. Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on .
(Any unentered amendment(s) referred to above will be entered.)
 - ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on .
 - iii. Other:
 - b. Enclosed is/are:
 - i. Amendment/Reply (Appendix A – Marked-up Claims)
 - ii. Affidavit(s)/Declaration(s)
 - iii. Information Disclosure Statement (IDS)
 - iv. Other: Lemaitre Abstract
2. Miscellaneous
 - a. Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of ___ months. (Period of suspension shall not exceed 3 months) and the Fee of \$130.00 under 37 C.F.R. § 1.17(i) is enclosed.
 - b. Other:
3. Fees - The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when the RCE is filed.
 - a. Enclosed is a check in the amount of \$830.00 which covers:
 - i. RCE fee required under 37 C.F.R. § 1.17(e) – small entity
 - ii. Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) – small entity
 - iii. Other
4. If the filing of this RCE necessitates an extension of time under 37 CFR § 1.136(a), the applicant hereby requests such extension of time.
5. If there is no check enclosed, or if the amount of the enclosed check in this RCE is incorrect, the Director is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 23/2825.

11/15/2002 EN807EN 00000038 09620783

01 FC:2801
02 FC:2253

370.00 OP
460.00 OP

6. CORRESPONDENCE ADDRESS

Correspondence address below

CUSTOMER NUMBER:




23628

OR

ATTORNEY'S NAME	Maria A. Trevisan, Reg. No. 48,207				
FIRM NAME	Wolf, Greenfield & Sacks, P.C.				
ADDRESS	600 Atlantic Avenue				
CITY	Boston	STATE	MA	ZIP	02210
COUNTRY	USA	TELEPHONE	(617) 720-3500	FAX	(617) 720-2441
7. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED					
NAME	Maria A. Trevisan, Reg. No. 48,207				
SIGNATURE					
DATE	November 7, 2002				

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to **BOX RCE**, Commissioner for Patents, Washington, D.C. 20231, on the 7th day of November, 2002.


Maria A. Trevisan

1: Proc Natl Acad Sci U S A 1987 Feb;84(3):648-52

Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site.

Lemaitre M, Bayard B, Lebleu B.

Antisense oligonucleotides represent an interesting tool for selective inhibition of gene expression, but their efficient introduction within intact cells proved to be difficult to realize. As a step toward this goal, small (13- or 15-mer) synthetic oligodeoxyribonucleotides have been coupled at their 3' ends to epsilon-amino groups of lysine residues of poly(L-lysine) (Mr, 14,000). A 15-mer oligonucleotide-poly(L-lysine) conjugate complementary to the initiation region of vesicular stomatitis virus (VSV) N-protein mRNA specifically inhibits the synthesis of VSV proteins and exerts an antiviral activity against VSV when added in the cell culture medium at doses as low as 100 nM. Neither synthesis of cellular proteins nor multiplication of encephalomyocarditis virus was affected significantly by this oligonucleotide conjugate. The data suggest that oligonucleotide-poly(L-lysine) conjugates might become effective for studies on gene expression regulation and for antiviral chemotherapy.

PMID: 3027696 [PubMed - indexed for MEDLINE]

